Allianz Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Allianz Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$129K	Sell	15,200 -12,100	-44%	-$115K	﹤0.01%	1955
2025 Q4	$331K	Sell	27,300 -15,400	-36%	-$187K	﹤0.01%	1883
2025 Q3	$499K	Sell	42,700 -18,500	-30%	-$221K	﹤0.01%	1841
2025 Q2	$568K	Buy	61,200 +23,700	+63%	+$185K	﹤0.01%	1801
2025 Q1	$275K	Sell	37,500 -27,000	-42%	-$208K	﹤0.01%	2060
2024 Q4	$551K	Buy	64,500 +20,700	+47%	+$202K	﹤0.01%	1834
2024 Q3	$381K	Buy	+43,800	New	+$361K	﹤0.01%	1925
2015 Q2	–	Sell	-53,045	Closed	-$2.23M	–	2465
2015 Q1	$2.23M	Buy	+53,045	New	+$1.74M	﹤0.01%	1490

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Allianz Asset Management's OCUL Position: Q1 2026 in Review

Allianz Asset Management reduced its Ocular Therapeutix (OCUL) stake by 44% in Q1 2026, selling an estimated $115K and leaving 15,200 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Allianz Asset Management first reported a position in OCUL in Q1 2015 and has held it in 8 quarters since. The position peaked at $2.23M in Q1 2015. 270 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Allianz Asset Management held 15,200 shares of Ocular Therapeutix worth $129K as of Q1 2026.
Allianz Asset Management sold 12,100 Ocular Therapeutix shares in Q1 2026, an estimated $115K.
Ocular Therapeutix made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1955 holding.
Allianz Asset Management first reported a position in Ocular Therapeutix in Q1 2015 and has held it in 8 quarters since.
Allianz Asset Management's Ocular Therapeutix position peaked at $2.23M in Q1 2015.
270 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.